Table 3.
Later-onset AEFI reported by AusVaxSafety participants following live attenuated herpes zoster vaccine live (ZVL) by sex, concomitant vaccination and underlying medical condition (initial survey)*
| Males n (%) |
Females n (%) |
RR (95% CI) (female vs male) | ZVL alone n (%) |
ZVL +concomitant vaccine/s n (%) | RR (95% CI) (concomitant vs ZVL alone) | No medical condition n (%) |
Medical condition n (%) |
RR (95% CI) (medical condition vs no condition) | |
| Any AEFI | 19 (11.7) | 33 (18.0) | 1.55 (0.92 to 2.61) | 46 (15.9) | 6 (10.5) | 0.66 (0.30 to 1.48) | 28 (13.8) | 24 (16.8) | 1.22 (0.74 to 2.01) |
| Injection site reaction | 6 (3.7) | 17 (9.3) | 2.52 (1.02 to 6.25) | 19 (6.6) | 4 (7.0) | 1.07 (0.38 to 3.02) | 13 (6.4) | 10 (7.0) | 1.09 (0.49 to 2.42) |
| Fever | 2 (1.2) | 6 (3.3) | 2.67 (0.55 to 13.1) | 8 (2.8) | 0 (0.0) | NA | 2 (1.0) | 6 (4.2) | 4.26 (0.87 to 20.8) |
| Rash | 3 (1.8) | 5 (2.7) | 1.48 (0.36 to 6.12) | 7 (2.4) | 1 (1.8) | 0.72 (0.09 to 5.77) | 5 (2.5) | 3 (2.1) | 0.85 (0.21 to 3.51) |
| Medical attendance † | 2 (1.2) | 4 (2.2) | 1.78 (0.33 to 9.60) | 5 (1.7) | 1 (1.8) | 1.01 (0.12 to 8.52) | 4 (2.0) | 2 (1.4)‡ | 0.71 (0.13 to 3.82) |
*Denominator includes Vaxtracker participants responding within 7 days to an initial opt-in survey by SMS or email sent 16 days following vaccination (M: 163, F: 183, total: 346). Of these, 57 had received a concomitant vaccine and 143 had an underlying medical condition.
†All those reporting medical attendance reported visiting a primary care provider.
‡One participant had arthritis and one had diabetes.
AEFI, adverse events following immunisation; NA, not available; SMS, short message service.